Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

References

• Drenberg CD, Baker SD, Sparreboom A. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013;93:215–219.
   PubMed Web of Science ®Google Scholar
• Humphrey R, Brockway-Lunardi L, Bonk D, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Nat Cancer Inst. 2011;103:1222–1226.
   PubMed Web of Science ®Google Scholar
• Eckstein N, Röper L, Haas B, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res. 2014;33:15.
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–979.
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187.
   PubMed Web of Science ®Google Scholar
• McTigue M, Murray BW, Chen JH, et al. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci. 2012;109:18281–18289.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tortorici MA, Garrett M, et al. Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013;52:713–725.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Cohen EE, Pithavala YK, et al. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014;74:1279–1289.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55:1012–1023.
   PubMed Web of Science ®Google Scholar
• Nair A, Lemery SJ, Yang J, et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2015;21:5205–5208.
   PubMed Web of Science ®Google Scholar
• FDA. OFEV (nintedanib) prescribing information 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
   Google Scholar
• Deng Y, Sychterz C, Suttle AB, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43:443–453.
   PubMed Web of Science ®Google Scholar
• Imbs D-C, Négrier S, Cassier P, et al. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014;73:1189–1196.
   PubMed Web of Science ®Google Scholar
• Bruix J, Tak W-Y, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412–3419.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–972.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271–7278.
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367–1373.
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35.
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34:221–237.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69:1051–1061.
   PubMed Web of Science ®Google Scholar
• Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52:1101–1109.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005;11:6414–6421.
   PubMed Web of Science ®Google Scholar
• Frohna P, Lu J, Eppler S, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46:282–290.
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet. 2005;44:1165–1177.
   PubMed Web of Science ®Google Scholar
• Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther. 2004;29:95–103.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305–5313.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Jones SF, Koch KM, et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol. 2008;26:3051–3056.
   PubMed Web of Science ®Google Scholar
• FDA. TAGRISSO (osimertinib) prescribing information 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf
   Google Scholar
• FDA. ALECENSA (alectinib) prescribing information 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf
   Google Scholar
• Lau YY, Gu W, Lin T, et al. Effects of meal type on the oral bioavailability of the ALK inhibitor, ceritinib, in healthy adult subjects. J Clin Pharmacol. 2016;56:559–566.
   PubMed Web of Science ®Google Scholar
• Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Dev Ther. 2011;5:471–485.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Johnson TR, Smith BJ. Prediction of drug-drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model. Drug Metab Dispos. 2015;43:1417–1429.
   PubMed Web of Science ®Google Scholar
• Takahashi RH, Choo EF, Ma S, et al. Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos. 2016;44:28–39.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2014;20:4449–4458.
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773–781.
   PubMed Web of Science ®Google Scholar
• Kim G, McKee AE, Ning YM, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014;20:4994–5000.
   PubMed Web of Science ®Google Scholar
• Solimando DA, Waddell JA. Drug monographs: bosutinib and regorafenib. Hosp Pharm. 2013;48:190–194.
   PubMedGoogle Scholar
• Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14:352–359.
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–942.
   PubMed Web of Science ®Google Scholar
• Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome–positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008;14:5325–5331.
   PubMed Web of Science ®Google Scholar
• Narasimhan NI, Dorer DJ, Davis J, et al. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2014;74:341–348.
   PubMed Web of Science ®Google Scholar
• de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75:907–916.
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol. 2015;55:944–952.
   PubMed Web of Science ®Google Scholar
• FDA. JAKAFI (ruxolitinib) prescribing information 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s009lbl.pdf
   Google Scholar
• Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42:759–773.
   PubMed Web of Science ®Google Scholar
• FDA. IBRANCE (palbociclib) prescribing information 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf
   Google Scholar
• Burns K, Nair PC, Rowland A, et al. The nonspecific binding of tyrosine kinase inhibitors to human liver microsomes. Drug Metab Dispos. 2015;43:1934–1937.
   PubMed Web of Science ®Google Scholar
• Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551–603.
   PubMed Web of Science ®Google Scholar
• Scheffler M, Di Gion P, Doroshyenko O, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet. 2011;50:371–403.
   PubMed Web of Science ®Google Scholar
• Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92:203–213.
   PubMed Web of Science ®Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6:546–558.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar H-J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692–706.
   PubMed Web of Science ®Google Scholar
• de Graan A-JM, Lancaster CS, Obaidat A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012;18:4433–4440.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Neuvonen M, Laitila J, et al. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013;41:50–59.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014;42:1202–1209.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007;13:7394–7400.
   PubMed Web of Science ®Google Scholar
• Khan MS, Barratt DT, Somogyi AA. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica. 2016;46:278–287.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Van Gelder T, Mathijssen RHJ, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2013;15:e315–e326.
   Web of Science ®Google Scholar
• Reyner EL, Sevidal S, West MA, et al. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos. 2013;41:1575–1583.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Peric R, Hussaarts KGAM, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2016;34:1309–1314.
   PubMed Web of Science ®Google Scholar
• Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37:213–255.
   PubMed Web of Science ®Google Scholar
• Jain RK, Brar SS, Lesko LJ. Food and oral antineoplastics: more than meets the eye. Clin Cancer Res. 2010;16:4305–4307.
   PubMed Web of Science ®Google Scholar
• Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anti-Cancer Drugs. 2008;19:209–216.
   PubMed Web of Science ®Google Scholar
• Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs. 2006;17:353–358.
   PubMed Web of Science ®Google Scholar
• Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27:1191–1196.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Lin FPY, Miners JO, et al. Perpetrators of pharmacokinetic drug–drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71:727–736.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Tsunemitsu S, Maeda K, et al. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol. 2013;53:654–661.
   PubMed Web of Science ®Google Scholar
• Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93:275–282.
   PubMed Web of Science ®Google Scholar
• Kim R, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408–414.
   PubMed Web of Science ®Google Scholar
• Shao J, Markowitz JS, Bei D, et al. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci. 2014;103:3810–3833.
   PubMed Web of Science ®Google Scholar
• Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–1257.
   PubMed Web of Science ®Google Scholar
• Eskens F, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur J Cancer. 2006;42:3127–3139.
   PubMed Web of Science ®Google Scholar
• Yu H, Steeghs N, Nijenhuis C, et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305–325.
   PubMed Web of Science ®Google Scholar
• Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30:4017–4025.
   PubMed Web of Science ®Google Scholar
• Klümpen H-J, Samer CF, Mathijssen RHJ, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37:251–260.
   PubMed Web of Science ®Google Scholar
• Kloth JS, Klumpen HJ, Yu H, et al. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin Pharmacokinet. 2014;53:261–269.
   PubMed Web of Science ®Google Scholar
• de Wit D, Guchelaar H-J, den Hartigh J, et al. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today. 2015;20:18–36.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141–3147.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357–371.
   PubMed Web of Science ®Google Scholar
• Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008;98:1633–1640.
   PubMed Web of Science ®Google Scholar
• Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53:491–504.
   PubMed Web of Science ®Google Scholar
• Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol. 2007;18:761–767.
   PubMed Web of Science ®Google Scholar
• Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol. 2009;27:abstr 5045.
   Web of Science ®Google Scholar
• Tiseo M, Andreoli R, Gelsomino F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83:265–271.
   PubMed Web of Science ®Google Scholar
• Zhao Y-Y, Li S, Zhang Y, et al. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol. 2011;28:697–702.
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–3499.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–4028.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Kuroki J, et al. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Biomarker Res. 2014;2:6.
   PubMedGoogle Scholar
• Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68:723–733.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220–4227.
   PubMed Web of Science ®Google Scholar
• Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909–1916.
   PubMed Web of Science ®Google Scholar
• Yau T, Chen P-J, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17:6914–6923.
   PubMed Web of Science ®Google Scholar
• Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53:185–196.
   PubMed Web of Science ®Google Scholar
• Goulooze S, Martin J, Smith A. Therapeutic drug monitoring trials for gastrointestinal stromal tumors treated with sunitinib cannot be expected to detect clinical outcome improvement. ASCEPT-APSA Joint Scientific Meeting; 2015; Hobart. p. 524.
   Google Scholar
• Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110:2441–2449.
   PubMed Web of Science ®Google Scholar
• Zhang A, Fox P, Coulter S, et al. Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: a longitudinal study in metastatic renal cell cancer (mRCC). J Clin Oncol. 2014;32(suppl; abstr 2597).
   Google Scholar
• Mangoni A, Woodman R, Kichenadasse G, et al. Anti-VEGF-induced hypertension and cancer outcomes: translating research into clinical practice. Exp Rev Prec Med Drug Dev. 2016;1:125–127.
   Web of Science ®Google Scholar
• Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013;36:413–426.
   PubMed Web of Science ®Google Scholar
• Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14:3470–3476.
   PubMed Web of Science ®Google Scholar
• Sorich M, Rowland A, Kichenadasse G, et al. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer. 2016;114:1313–1317.
   PubMed Web of Science ®Google Scholar
• Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29:807–813.
   PubMed Web of Science ®Google Scholar
• Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42:742–747.
   PubMed Web of Science ®Google Scholar
• Clemons J, Gao D, Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012;10:225–231.
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology. 2003;17:23–28.
   PubMedGoogle Scholar
• Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006;8(Suppl 1):S7–S14.
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13:3913–3921.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78:8–15.
   PubMed Web of Science ®Google Scholar
• Mita AC, Papadopoulos K, De Jonge MJ, et al. Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 2011;105:938–944.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7:99–108.
   PubMed Web of Science ®Google Scholar
• Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7:797–809.
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010;150:303–312.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Huang X, Wiltshire R, et al. A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): pitfalls of efficacy subgroup analyses based on dose-reduction status. J Clin Oncol. 2012;suppl 5:abstr 363.
   Google Scholar
• Bjarnason GA, Khalil B, Hudson JM, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32:480–487.
   PubMed Web of Science ®Google Scholar
• Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1084–1089.
   PubMed Web of Science ®Google Scholar
• Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66:85–96.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Day L, Paramsothy T, et al. Oral anticancer medication adherence, toxicity reporting, and counseling: a study comparing health care providers and patients. J Oncol Prac. 2015;11:498–504.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann Oncol. 2015;26:13–21.
   PubMed Web of Science ®Google Scholar
• Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888–1894.
   PubMed Web of Science ®Google Scholar
• Rowland A, Dias MM, Wiese MD, et al. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer. 2016;55:122–130.
   PubMed Web of Science ®Google Scholar
• Elens L, Van Gelder T, Hesselink DA, et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013;14:47–62.
   PubMed Web of Science ®Google Scholar
• Shin K-H, Choi MH, Lim KS, et al. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013;94:601–609.
   PubMed Web of Science ®Google Scholar
• Ravegnini G, Sammarini G, Angelini S, et al. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Expert Opin Drug Metabol Toxicol. 2016;12:733–742.
   PubMed Web of Science ®Google Scholar
• Wang D, Sadee W. The making of a CYP3A biomarker panel for guiding drug therapy. J Personal Med. 2012;2:175–191.
   PubMedGoogle Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–181.
   PubMed Web of Science ®Google Scholar
• Lancaster CS, Sprowl JA, Walker AL, et al. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther. 2013;12:1537–1544.
   PubMed Web of Science ®Google Scholar
• Snyder BD, Rowland A, Polasek TM, et al. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70:1115–1122.
   PubMed Web of Science ®Google Scholar
• Mårde Arrhén Y, Nylén H, Lövgren-Sandblom A, et al. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. Br J Clin Pharmacol. 2013;75:1536–1540.
   PubMed Web of Science ®Google Scholar
• Shen H, Dai J, Liu T, et al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther. 2016;357:382–393.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
   PubMed Web of Science ®Google Scholar
• Rowland A, Dias MM, Wiese MD, et al. Reply: comment ‘meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer’. Br J Cancer. 2015;113:1635.
   PubMed Web of Science ®Google Scholar
• Rowland A, Karapetis C, Mangoni A, et al. Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Transl Cancer Res. 2016;5:S31–S34.
   Web of Science ®Google Scholar